The Hallmarks of Aging, 2023 Update: Where Peptide-Class Bioregulators Fit in the Map

The January 2023 update to the Hallmarks of Aging framework, published in Cell by Lopez-Otin, Blasco, Partridge, Serrano, and Kroemer, is the most authoritative current map of the cellular biology of aging. It expanded the original 2013 framework from nine hallmarks to twelve, refined the mechanistic descriptions of several, and acknowledged the role of compounds and mechanisms that the 2013 framework had not addressed directly. Reading the updated framework carefully is now table stakes for any serious work in the longevity space.

We use this note to place peptide-class bioregulator compounds relative to the twelve hallmarks — not as a claim that bioregulators are the mechanism behind all twelve, but as an attempt to be specific about which hallmarks the bioregulator research lineage has direct evidence for, which it has indirect evidence for, and which it does not address.

Direct intersection: three hallmarks

• Epigenetic alteration — methylation patterns, chromatin remodelling, and transcriptional accessibility. Short-chain bioregulator peptides have been shown in multiple published studies to modulate gene expression patterns that overlap with the epigenetic landscape of aging. This is the primary mechanistic layer the bioregulator research operates on.
• Disabled macroautophagy and loss of proteostasis — the failure of cellular protein quality control systems. Bioregulator compounds have demonstrated effects on protein turnover machinery in tissue-specific contexts, particularly in liver, kidney, and immune compartments. Glycation, the third hallmark intersection, is the post-translational damage axis that accumulates when proteostasis fails.
• Altered intercellular communication — the breakdown of paracrine, endocrine, and neural signalling that coordinates tissue-level function. Bioregulator peptides act as information carriers in exactly this signalling architecture. The lineage of work that produced the modern bioregulator framework anticipated this hallmark by approximately three decades.

On glycation specifically

The 2023 update gave more emphasis than the original framework to advanced glycation end products (AGEs) and the broader category of protein damage that accumulates when cellular regulatory systems lose tone. Glycation is not its own named hallmark, but the role it plays sits at the intersection of proteostasis loss, mitochondrial dysfunction, and altered intercellular communication. The bioregulator framework intersects with the glycation layer through gene-expression effects on protein turnover, antioxidant defence systems, and the inflammatory cascade that accumulating AGEs activate.

This is one of the reasons the longevity supplement category needs more than substrate-replenishment interventions. Glycation cannot be supplemented away with a precursor. It is a regulatory and damage-clearance problem. Compounds that operate at the regulatory layer — including but not limited to peptide-class bioregulators — are the framework-consistent interventions for it.

“Glycation cannot be supplemented away with a precursor. It is a regulatory and damage-clearance problem. Compounds operating at the regulatory layer are the framework-consistent interventions for it.”

Indirect intersection: four hallmarks

Four additional hallmarks — mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and chronic inflammation — have indirect evidence in the bioregulator literature. Effects have been observed in animal models and in some human studies, but the mechanism by which the peptide-class compound produces the effect is downstream of the three hallmarks listed above rather than acting on these four directly. We describe these as supported but not the primary layer.

Hallmarks the bioregulator framework does not address directly

Genomic instability, telomere attrition, deregulated nutrient sensing, dysbiosis, and the deeper layers of stem cell biology are hallmarks that the bioregulator research lineage has not made primary claims about. Compounds and interventions that act on these hallmarks — telomerase activators, AMPK modulators, microbiome-directed therapies, and others — are complementary to, not displaced by, the bioregulator framework. The Opticeutical category does not require all twelve hallmarks to be addressed by a single compound class. It requires that the compounds the category endorses act on the hallmarks they act on, with evidence proportionate to the claim.

Why a framework reading matters at the category level

The supplement industry has historically been promiscuous with framework references — invoking the Hallmarks of Aging to support claims that the framework does not actually license. The Opticeutical Standard's mechanism rationale pillar exists to prevent this drift. A product claiming epigenetic effect must demonstrate epigenetic effect. A product claiming proteostasis effect must demonstrate proteostasis effect. The Hallmarks framework is the most rigorous current map; the Standard's job is to make sure claims under that map are anchored where they actually anchor. Further treatment of how the Hallmarks framework informs the Standard is documented at the institutional reference.